The pharmaceutical landscape is currently undergoing a period of rapid, technology-driven transformation. From the rise of complex biologics and lipid nanoparticles to the relentless pursuit of cost-effective manufacturing, the industry is grappling with how to maintain rigorous quality standards while fostering necessary innovation. Addressing these challenges requires a bridge between regulatory foresight and scientific execution.
To that end, the American Association of Pharmaceutical Scientists (AAPS) and the United States Pharmacopeia (USP) have announced a major expansion of their collaborative efforts for the upcoming 2026 PharmSci 360 conference. Scheduled for October 25–28 at the Ernest N. Morial Convention Center in New Orleans, the event promises to be a pivotal nexus for industry leaders, regulators, and academic researchers.
The Evolution of the AAPS-USP Partnership
The collaboration between AAPS and USP is not a new development, but rather the culmination of years of increasing engagement. In previous iterations of PharmSci 360, the USP has utilized the conference as a platform to demystify compendial standards.
In 2023, the focus was centered on the nuance of excipient and raw material grades—a critical topic for formulation scientists—while the 2025 meeting saw an increase in activity through exhibit-hall stage sessions. However, the 2026 conference represents a structural shift. Moving beyond sporadic talks, the partnership will culminate in a dedicated, two-and-a-half-day workshop, signaling a commitment to deep-dive technical education rather than high-level overview sessions.
The Workshop: A Deep Dive into Quality and Compliance
The centerpiece of this year’s collaboration is a comprehensive workshop running from October 26 to October 28 within the exhibit hall. This intensive program is designed to provide actionable intelligence regarding the USP–NF (United States Pharmacopeia–National Formulary), the collection of public standards that serve as the bedrock for quality specifications enforceable by the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act.
Key Focus Areas of the Workshop:
- Complex Generics: As the patent cliff looms for several major blockbusters, the industry is focusing on the regulatory pathways for complex generic formulations. The workshop will address the specific quality hurdles inherent in these products.
- Excipient Quality and Novel Excipients: The functionality of excipients is no longer merely a background consideration; it is a primary driver of drug performance. The sessions will explore the regulatory challenges of integrating novel excipients into existing supply chains.
- Inhalation Standards: Given the sensitivity of drug delivery through inhalation, the workshop will detail the evolving standards required to ensure particle size consistency and delivery reliability.
While the speaker roster remains under wraps, the breadth of the topics suggests an agenda curated for both analytical chemists and regulatory affairs professionals who are tasked with aligning their development pipelines with federal requirements. Additionally, the USP will maintain a prominent presence at Booth 2931, complemented by a specialized poster collection detailing recent advances in pharmacopeial science.
Chronology of Scientific Engagement: The Main Program
Beyond the dedicated workshop, the USP is deeply embedded in the main scientific program of PharmSci 360. This integration serves to influence the broader conversation surrounding pharmaceutical development, with USP staff participating in pivotal roles as both moderators and subject matter experts.
Monday: The Future of Biologics
A significant highlight of the Monday agenda is the symposium on the future of public standards for biologics development. Featuring a panel of industry titans, the session will be moderated by Allison Radwick, Ph.D., senior regulatory and policy communications manager at USP.
The symposium promises to tackle the “billion-dollar questions” of the industry:
- The $10-per-gram Goal: Anurag Rathore, Ph.D., from the Indian Institute of Technology Delhi, will lead a discussion on whether next-generation platforms can realistically produce monoclonal antibodies at a price point of $10 per gram—a goal that could revolutionize global access to life-saving medicines.
- Formulation Science: Tongzhou Liu, Ph.D., of AbbVie’s product development science and technology group, will share insights into the strategic formulation choices required in modern commercial manufacturing.
- Nanotechnology Integration: Luis Brito, Ph.D., of Moderna, will provide a deep dive into lipid nanoparticles, a technology that gained global prominence during the pandemic and continues to redefine drug delivery.
Keynotes and Predictive Development
Ravi Kiran Kaja, Ph.D., a senior principal scientist at USP, will moderate two high-impact keynote sessions. The first, featuring Alan Watts, Ph.D., of Catalent, will analyze the complex scale-up process of Inbrija, a critical case study in overcoming the challenges of transitioning from clinical to commercial manufacturing.
The second keynote features Shawn Zhang, Ph.D., of digiM Solution, who will explore microstructure-based predictive development. This session highlights the industry’s shift toward “digital twins” and advanced simulation, which allow companies to predict performance before the first batch is even manufactured.
Perspectives on Quality and Innovation
The decision to expand the collaboration between USP and AAPS is rooted in a shared philosophy: that innovation cannot exist in a vacuum. Without standardized quality, the risks to patient safety—and the economic risks to the developer—are insurmountable.
“USP and AAPS are aligned in our shared mission to help industry and regulators address evolving challenges in pharmaceutical quality,” said Catherine Sheehan, senior director of growth programs for excipients and foods at USP. “This workshop will bring together a range of stakeholder perspectives to foster innovation, strengthen regulatory confidence, and ultimately help increase the availability of quality medicines for the patients who need them.”
This sentiment underscores the broader mission of PharmSci 360. The conference is designed to span the entire development lifecycle, from preclinical research and translational sciences to formulation, delivery, and analytical characterization. By embedding USP’s standards-setting expertise into these conversations, the conference ensures that scientists are not just building for the sake of the “new,” but building for the sake of the “stable and safe.”
Implications for the Industry
The implications of the 2026 PharmSci 360 conference for the pharmaceutical industry are threefold:
1. Regulatory De-risking
By participating in the USP workshops, attendees gain an early understanding of how quality specifications are shifting. For firms engaged in the development of novel excipients or complex generics, this information is the difference between a smooth FDA approval process and years of costly, data-heavy inquiries.
2. Standardization of Emerging Tech
Technologies like lipid nanoparticles and next-generation monoclonal antibody manufacturing are currently ahead of the traditional regulatory curve. The discussions at PharmSci 360 serve as a vital feedback loop. When researchers like those at Moderna and IIT Delhi share their findings, the USP gains the necessary context to develop public standards that are both rigorous and practically achievable for the industry.
3. Fostering Collaboration
The conference acts as a rare meeting ground where regulators, academic researchers, and commercial developers speak the same language. In an era where supply chain resilience and drug shortages are global concerns, the ability to align on quality standards is a prerequisite for a more stable pharmaceutical market.
Looking Ahead
As the industry prepares for New Orleans this October, the focus remains on the intersection of speed and reliability. The 2026 AAPS PharmSci 360 conference is positioned not merely as a networking event, but as a critical infrastructure summit. By synthesizing the latest in analytical technology with the enduring requirement for rigorous pharmacopeial standards, the collaboration between AAPS and USP provides a roadmap for the future of pharmaceutical development.
Attendees are encouraged to review the full 2026 PharmSci 360 conference program to map out their schedules, as the overlap between the main scientific tracks and the USP-led workshops will undoubtedly present a crowded, yet essential, agenda for any professional involved in the drug development pipeline.
About the Author
